Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Treatment Concerns for Bullous Pemphigoid in the Covid-19 Pandemic Era Publisher Pubmed



Azimi SZ1 ; Firooz A1 ; Murrell DF2 ; Daneshpazhooh M3
Authors

Source: Dermatologic Therapy Published:2020


Abstract

Bullous pemphigoid (BP) is the most common autoimmune blistering disease with subepidermal involvement, typically affecting the elderly. It has spontaneous remissions and exacerbations with significant morbidity. A novel coronavirus called severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for the new universal coronavirus disease 2019 (COVID-19) pandemic. The pandemic made concerns, especially about immunosuppressive therapy. In this article, we reviewed the management of BP in the COVID-19 pandemic era. The data about the best management of autoimmune bullous diseases like BP, during the outbreak of COVID-19, are evolving and updated every day. © 2020 Wiley Periodicals LLC.
Other Related Docs
5. Bullous Pemphigoid, Nature Reviews Disease Primers (2025)
11. Potential Therapeutic Options for Covid-19: An Update on Current Evidence, European Journal of Medical Research (2022)
14. Covid-19: Significance of Antibodies, Human Antibodies (2020)
15. Epidemiological Study of Covid-19 in Iran and the World: A Review Study, Infectious Disorders - Drug Targets (2022)
16. Molecular Aspects of Co-Morbidities in Covid-19 Infection, Archives of Bone and Joint Surgery (2020)
18. Covid-19 in Patients With Cancer: Risks and Precautions, American Journal of Emergency Medicine (2021)
20. The Immunologic Basis of Covid-19: A Clinical Approach, Journal of Cellular and Molecular Anesthesia (2020)